Safety, tolerablity and efficacy of a metabolically active, non-replicating, whole organism malaria vaccine (PfSPZ Vaccine) in malaria-experienced adults in Burkina Faso
Description
Presented at the Multilateral Initiative on Malaria Pan African Malaria Conference in Dakar, Senegal in April 2018 on the behalf of the PfSPZ Vaccine in Burkina Faso study teamSponsors
National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under U01 AIl112367IKeyword
Sanaria PfSPZ vaccineUniversity of Maryland, Baltimore. School of Medicine. Center for Vaccine Development and Global Health
Burkina Faso
Malaria Vaccines